Stanford University School of Medicine, Stanford, USA.
Section of Surgical Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, USA.
Ann Surg Oncol. 2024 Jun;31(6):3769-3777. doi: 10.1245/s10434-024-15120-3. Epub 2024 Mar 11.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for patients with peritoneal carcinomatosis is promising but has potential for significant morbidity and prolonged hospitalization. Enhanced Recovery After Surgery (ERAS) is a standardized protocol designed to optimize perioperative care. This study describes trends in epidural and opioid use after implementing ERAS for CRS-HIPEC at a tertiary academic center.
A retrospective analysis of patients undergoing CRS-HIPEC from January 2020 to September 2023 was conducted. ERAS was implemented in February 2022. Medication and outcomes data were compared before and after ERAS initiation. All opioids were converted to morphine milligram equivalents (MMEs).
A total of 136 patients underwent CRS-HIPEC: 73 (54%) pre- and 63 (46%) post-ERAS. Epidural usage increased from 63% pre-ERAS to 87% post-ERAS (p = 0.001). Compared with those without epidurals, patients with epidurals had decreased total 7-day oral and intravenous (IV) opioid requirements (45 MME vs. 316 MME; p < 0.001). There was no difference in 7-day opioid totals between pre- and post-ERAS groups. After ERAS, more patients achieved early ambulation (83% vs. 53%; p < 0.001), early diet initiation (81% vs. 25%; p < 0.001), and early return of bowel function (86% vs. 67%; p = 0.012).
ERAS implementation for CRS-HIPEC was associated with increased epidural use, decreased oral and IV opioid use, and earlier bowel function return. Our study demonstrates that epidural analgesia provides adequate pain control while significantly decreasing oral and IV opioid use, which may promote gastrointestinal recovery postoperatively. These findings support the implementation of an ERAS protocol for effective pain management in patients undergoing CRS-HIPEC.
细胞减灭术联合腹腔内热灌注化疗(CRS-HIPEC)治疗腹膜癌转移患者具有广阔的前景,但也存在较高的发病率和较长的住院时间。加速康复外科(ERAS)是一种标准化的方案,旨在优化围手术期的护理。本研究描述了在一家三级学术中心实施 CRS-HIPEC 后的硬膜外和阿片类药物使用趋势。
对 2020 年 1 月至 2023 年 9 月期间接受 CRS-HIPEC 的患者进行回顾性分析。ERAS 于 2022 年 2 月实施。比较 ERAS 前后的药物和结局数据。所有阿片类药物均转换为吗啡毫克当量(MME)。
共有 136 例患者接受了 CRS-HIPEC:73 例(54%)为 ERAS 前,63 例(46%)为 ERAS 后。硬膜外使用率从 ERAS 前的 63%增加到 ERAS 后的 87%(p = 0.001)。与未使用硬膜外的患者相比,使用硬膜外的患者术后 7 天口服和静脉(IV)阿片类药物的总需求减少(45 MME 比 316 MME;p < 0.001)。ERAS 前后两组的 7 天阿片类药物总量无差异。实施 ERAS 后,更多的患者实现了早期活动(83%比 53%;p < 0.001)、早期进食(81%比 25%;p < 0.001)和更早的肠道功能恢复(86%比 67%;p = 0.012)。
CRS-HIPEC 中实施 ERAS 与硬膜外使用率增加、口服和 IV 阿片类药物使用减少以及更早的肠道功能恢复有关。我们的研究表明,硬膜外镇痛可以提供充分的疼痛控制,同时显著减少口服和 IV 阿片类药物的使用,这可能促进术后胃肠道的恢复。这些发现支持在接受 CRS-HIPEC 的患者中实施 ERAS 方案以进行有效的疼痛管理。